Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)

Main Article Content

K Gordon
R B Warren
A B Gottlieb
A Blauvelt
D Tha?i
Y Poulin
M Boehnlein
F Brock
C Arendt
K Reich


Psoriasis, Biologics, Certolizumab, efficacy


Abstract not available.


1. Gottlieb A.B. et al. JAAD 2018;79:302–14.e6;

2. Lebwohl M. et al. JAAD 2018;79:266–76.e5.

Most read articles by the same author(s)

1 2 3 4 > >>